The Endoscopy Ultrasound Market size was estimated at USD 1.52 billion in 2025 and expected to reach USD 1.64 billion in 2026, at a CAGR of 8.06% to reach USD 2.62 billion by 2032.

Endoscopy ultrasound, more precisely endoscopic ultrasound or EUS, is a high-value diagnostic and therapeutic modality that combines endoscopic visualization with ultrasound imaging to evaluate the gastrointestinal tract and adjacent organs, including the pancreas, bile ducts, mediastinum, lymph nodes, and subepithelial lesions. The clinical relevance of EUS is reinforced by pancreatic cancer’s global burden: IARC reports that more than 500,000 people were diagnosed with pancreatic cancer in 2022 and almost 470,000 died from the disease, making it the sixth leading cause of cancer death worldwide despite being the 12th most common cancer type. For healthcare systems, EUS supports precision diagnosis, EUS-guided tissue acquisition, pancreatic cancer staging, biliary evaluation, drainage procedures, and pain interventions while helping multidisciplinary teams reduce diagnostic uncertainty.

The endoscopy ultrasound landscape is shifting from procedure-centric imaging toward integrated pancreaticobiliary and oncology care. Updated evidence-based guidance recommends fine-needle biopsy over fine-needle aspiration for EUS-guided tissue acquisition in solid pancreatic masses, reflecting the growing importance of core tissue, molecular profiling, and reproducible pathology workflows. Therapeutic EUS is also moving beyond niche use, with guideline support for EUS-guided biliary drainage after failed ERCP in malignant distal biliary obstruction when local expertise is available, while complex pancreatic duct drainage is reserved for high-volume expert centers. These shifts elevate the importance of clinician training, image quality, pathology coordination, infection prevention, sedation readiness, and referral triage.

Artificial intelligence is adding cumulative value to endoscopic ultrasound by supporting lesion detection, pattern recognition, quality assurance, documentation, and decision support for pancreatic and gastrointestinal disease. Meta-analytic evidence has reported strong diagnostic performance for AI-assisted EUS in pancreatic cancer and pancreatic tumors, including pooled sensitivity and specificity values above 90% in published studies, but the evidence base remains dependent on dataset diversity, external validation, prospective testing, and clinician oversight. AI governance is now a strategic requirement: WHO guidance emphasizes ethics, human rights, autonomy, privacy, and safety in AI for health, while European rules classify medical-purpose AI software as high risk when applicable and require risk mitigation, high-quality data, clear user information, and human oversight.

Asia-Pacific is a core endoscopy ultrasound priority because Asia represented 46.4% of global five-year pancreatic cancer prevalence in GLOBOCAN 2022, while Japan, China, India, South Korea, and Australia combine large disease burdens with very different levels of advanced imaging and specialist access. North America benefits from mature cancer registries, advanced endoscopy training pathways, and guideline-led use of EUS-guided tissue acquisition, with Canada’s 2022 cancer profile showing pancreas as a leading mortality contributor despite fewer incident cases than lung or colorectal cancer. Latin America’s opportunity is strongest in Brazil and Mexico, where cancer burden intersects with uneven access to advanced endoscopy and the need for hub-based referral pathways. Europe shows high procedural sophistication and a substantial pancreatic cancer burden, with GLOBOCAN reporting 26.7% of global five-year pancreatic cancer prevalence in Europe and Germany listing pancreas among its leading causes of cancer death. The Middle East is shaped by rising gastrointestinal cancer needs across Eastern Mediterranean systems, while Africa’s priority is capacity building, maintenance, workforce training, and reliable referral because published evidence shows endoscopy capacity gaps in parts of the continent.

ASEAN’s endoscopy ultrasound pathway is tied to health-system resilience, universal health coverage, NCD risk reduction, and screening of people at risk, priorities reflected in the ASEAN Socio-Cultural Community Strategic Plan. GCC systems are positioned for coordinated advanced endoscopy development because regional health statistics track hospitals, beds, doctors, and other planning indicators across member states, supporting standardized service design and capacity decisions. The European Union is defined by regulatory rigor, with medical AI and health-data frameworks shaping how AI-assisted EUS, clinical decision support, and device software are evaluated. BRICS brings together major Global South health systems, including large pancreaticobiliary and gastrointestinal disease populations, making affordability, training scale, local evidence generation, and referral integration central to EUS adoption. G7 countries anchor high-acuity innovation and evidence-based practice through advanced cancer care networks, digital health policy, and clinical governance, while NATO emphasizes interoperability, medical readiness, digital surveillance, and cross-border medical standards that can influence deployable and resilient specialty-care models.

In the United States, EUS is guided by evidence-based recommendations for solid pancreatic masses, biliary strictures, and therapeutic biliary interventions, making EUS-guided tissue acquisition, same-session coordination with ERCP, and molecular-ready sampling central to clinical pathways. Canada’s structured cancer registry environment supports referral prioritization for pancreaticobiliary disease, while Mexico and Brazil require scalable specialist networks that improve access outside major urban centers. The United Kingdom, Germany, France, Italy, and Spain are supported by established endoscopy and oncology infrastructures, with Germany’s profile showing pancreas as the third-ranked cause of cancer death in 2022; Russia’s pathway depends on standardized referral, equipment maintenance, and workforce consistency across large geographies. In Asia-Pacific, China and India face high absolute cancer burdens that make scalable EUS training and triage essential, Japan and South Korea combine high procedural sophistication with strong gastrointestinal cancer programs, and Australia’s role centers on quality standards, training, and referral integration across dispersed populations.

Industry leaders should prioritize clinically validated EUS platforms, tissue-acquisition workflows, and service models that improve diagnostic confidence without increasing avoidable procedural burden. Investment should focus on endoscopist training, pathology coordination, standardized reporting, AI-ready image governance, cybersecurity, lifecycle monitoring, and interoperability with electronic records and oncology boards. For advanced therapeutic EUS, leaders should restrict complex procedures to credentialed, high-volume centers while building referral pathways that move appropriate patients quickly from cross-sectional imaging to EUS-guided diagnosis or intervention. AI-assisted EUS should be deployed as clinician-supervised decision support, supported by prospective validation, bias monitoring, transparent labeling, and post-deployment performance review. Access strategies should also include scope reprocessing quality, maintenance resilience, tele-mentoring, regional training hubs, and evidence generation in underrepresented populations.

The research methodology uses a secondary, evidence-led approach that triangulates clinical practice guidelines, peer-reviewed systematic reviews, public cancer registries, health-system publications, regulatory guidance, and regional policy documents. Sources were screened for relevance to endoscopic ultrasound, EUS-guided tissue acquisition, pancreaticobiliary disease, therapeutic EUS, artificial intelligence governance, regional access, and country-level cancer burden. Priority was assigned to public health agencies, cancer observatory datasets, professional clinical guidelines, and indexed medical literature. The analysis deliberately excludes market estimation, market sizing, market share, and forecasting, focusing instead on clinical utility, burden indicators, adoption enablers, regulatory direction, care-delivery constraints, and evidence-backed strategic implications for the endoscopy ultrasound ecosystem.

Endoscopy ultrasound is evolving into a precision-care platform for gastrointestinal oncology, pancreaticobiliary diagnosis, and minimally invasive intervention. The strongest near-term value lies in EUS-guided tissue acquisition, pancreatic cancer diagnosis and staging, biliary drainage after failed ERCP in appropriate settings, and standardized care pathways that connect imaging, pathology, oncology, and therapeutic endoscopy. AI can strengthen consistency and workflow efficiency, but its impact depends on validated datasets, human oversight, and regulatory alignment. Regions and countries with mature endoscopy infrastructures should deepen quality governance and advanced therapeutic capability, while emerging systems should prioritize workforce development, referral design, maintenance capacity, and equitable access. The strategic imperative is clear: align EUS technology, training, evidence, and digital governance around measurable clinical outcomes.